HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas

Ersoy, Esma; Cao, Qing; Otis, Christopher N.

doi:10.1097/pgp.0000000000000812

Cited by 6 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies[ 6 - 10 ] have demonstrated that the HER2 gene is overexpressed in multiple tumor types, including breast, lung, ovarian, prostate, and colorectal cancers. Around 20% of the patients with gastric cancer exhibit HER2 overexpression; these HER2-positive patients tend to have poor prognoses and are at higher risk of recurrence[ 5 , 11 ].…”

Section: Discussionmentioning

confidence: 99%

Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report

Zhou,

Yi,

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Human epidermal growth factor receptor-2 (HER-2) plays a vital role in tumor cell proliferation and metastasis. However, the prognosis of HER2-positive gastric cancer is poor. Inetetamab, a novel anti-HER2 targeting drug independently developed in China, exhibits more potent antibody-dependent cell-mediated cytotoxicity than trastuzumab, which is administered as the first-line treatment for HER2-positive gastric cancer in combination with chemotherapy. In this case, the efficacy and safety of inetetamab combined with tegafur was investigated as a second-line treatment for HER2-positive gastric cancer. CASE SUMMARY A 52-year-old male patient with HER2-positive gastric cancer presented with abdominal distension, poor appetite, and fatigue two years after receiving six cycles of oxaliplatin combined with tegafur as first-line treatment after surgery, followed by tegafur monotherapy for six months. The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma. He received 17 cycles of a combination of inetetamab, an innovative domestically developed anti-HER2 monoclonal antibody, and tegafur chemotherapy as the second-line treatment (inetetamab 200 mg on day 1, every 3 wk combined with tegafur twice daily on days 1–14, every 3 wk). Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition and progression-free survival of 17 months. He tolerated the treatment well without exhibiting any grade 3-4 adverse events. CONCLUSION Inetetamab combined with chemotherapy for the treatment of metastatic HER2-positive gastric cancer demonstrates significant survival benefits and acceptable safety.

show abstract

Section: Discussionmentioning

confidence: 99%

Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report

Zhou,

Yi,

et al. 2024

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…82,[86][87][88][89] HER2-positivity rates are much lower in ovarian high-grade serous carcinoma than in USC, with overexpression/amplification seen in only 2%-4% of cases, and low response rates in those treated with targeted therapy. [91][92][93] Limited data also suggest low HER2positivity rates in ovarian carcinosarcoma, at less than 10%. 90 Higher rates of HER2 overexpression/ amplification have been reported in ovarian mucinous tumours, mostly mucinous carcinomas with concurrent TP53 mutations.…”

Section: Her2 Biomarker Expression In Other Gynaecologic Malignanciesmentioning

confidence: 99%

“…HER2‐positivity rates are much lower in ovarian high‐grade serous carcinoma than in USC, with overexpression/amplification seen in only 2%–4% of cases, and low response rates in those treated with targeted therapy 91–93 . Limited data also suggest low HER2‐positivity rates in ovarian carcinosarcoma, at less than 10% 90 .…”

Section: Her2 Scoring Systems and Readouts In Human Solid Tumoursmentioning

confidence: 99%

HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls

Zhang,

Finkelman,

Ettel

et al. 2024

Histopathology

View full text Add to dashboard Cite

The significant clinical benefits of human epidermal growth factor receptor 2 (HER2)‐targeted therapeutic agents have revolutionized the clinical treatment landscape in a variety of human solid tumours. Accordingly, accurate evaluation of HER2 status in these different tumour types is critical for clinical decision making to select appropriate patients who may benefit from life‐saving HER2‐targeted therapies. HER2 biomarker scoring criteria is different in different organ systems, and close adherence to the corresponding HER2 biomarker testing guidelines and their updates, if available, is essential for accurate evaluation. In addition, knowing the unusual patterns of HER2 expression is also important to avoid inaccurate evaluation. In this review, we discuss the key considerations when evaluating HER2 status in solid tumours for clinical decision making, including tissue handling and preparation for HER2 biomarker testing, as well as pathologist's readout of HER2 testing results in breast carcinomas, gastroesophageal adenocarcinomas, colorectal adenocarcinomas, gynaecologic carcinomas, and non‐small cell lung carcinomas.

show abstract

“…Protein expression studies on PD-L1, LAG3 and potential use of immunotherapeutic modalities on ovarian HGSCs have demonstrated modest therapeutic results and controversial prognosis [60][61][62]. Other dysregulated pathways in HGSCs are the PIK3CA/AKT and NOTCH pathways which can be therapeutically targeted by using PIK3CA or AKT inhibitors [63,64], whereas HER2 overexpression/ amplification (2-4% in HGSCs) has no significant impact on prognosis, albeit a finding that can be exploited for anti-HER2 targeted therapy [65,66].…”

Section: Molecular Pathology Of Ovarian High-grade Serous Carcinomasmentioning

confidence: 99%

Recent Advances in Classification and Histopathological Diagnosis of Ovarian Epithelial Malignant Tumours

Stanc¹,

Souka²,

Valavanis³

2023

Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer

View full text Add to dashboard Cite

Ovarian tumours are a heterogeneous group of neoplasms classified based on histopathologic type and grade of differentiation. They comprise a broad range of tumours from benign and borderline to malignant histotypes characterised by different histopathological, immunophenotypic and molecular features. The purpose of this chapter is to present an overview of the recent advances in the ovarian epithelial malignant tumours classification along with the histopathological, immunophenotypic and molecular diagnostic criteria highlighting areas of terminology discrepancies or changes and diagnostic challenges. These changes provide a better understanding of the ovarian tumours nature and lead to a more efficient therapeutic management of these pathological entities.

show abstract

HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas

Abstract: Individual and in-training subscription rates include print and access to the online version. Institutional rates are for print only; online subscriptions are available via Ovid. Institutions can choose to purchase a print and online subscription together for a discounted rate.

Cited by 6 publications

References 36 publications

Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report

Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report

HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls

Recent Advances in Classification and Histopathological Diagnosis of Ovarian Epithelial Malignant Tumours

Contact Info

Product

Resources

About